![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Long-acting subcutaneous lenacapavir dosed every 6 months as part of a combination regimen in treatment-naïve people with HIV: interim 16-week results of a randomized, open-label, phase 2 induction-maintenance study (CALIBRATE)
|
|
|
Samir GUPTA, United States
IAS 2021 July 18-22
![0720211](../images/072021/072021-14/0720211.gif)
![0720212](../images/072021/072021-14/0720212.gif)
![0720213](../images/072021/072021-14/0720213.gif)
![0720214](../images/072021/072021-14/0720214.gif)
![0720215](../images/072021/072021-14/0720215.gif)
![0720216](../images/072021/072021-14/0720216.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|